Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota

Posted by: | December 11, 2019 | Comments

ABSTRACT

Amelioration of metabolic syndrome by metformin associates with reduced indices of low-grade inflammation independently of the gut microbiota

Metformin beneficially impacts several aspects of metabolic syndrome including dysglycemia, obesity, and liver dysfunction, thus making it a widely used frontline treatment for early-stage type 2 diabetes, which is associated with these disorders. Several mechanisms of action for metformin have been proposed, including that it acts as an anti-inflammatory agent, possibly as a result of its impact on intestinal microbiota. In accord with this possibility, we observed herein that, in mice with diet-induced metabolic syndrome, metformin impacts the gut microbiota by preventing its encroachment upon the host, a feature of metabolic syndrome in mice and humans. However, the ability of metformin to beneficially impact metabolic syndrome in mice was not markedly altered by reduction or elimination of gut microbiota, achieved by the use of antibiotics or germfree mice.

Read more at: American Journal of Physiology-Endocrinology and Metabolism

Aneseh Adeshirlarijaney, Jun Zou, Hao Q. Tran, Benoit Chassaing, and Andrew T. Gewirtz. American Journal of Physiology-Endocrinology and Metabolism. DOI: https://doi.org/10.1152/ajpendo.00245.2019. 02 December 2019.





Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy




Terms & Conditions | Privacy Policy | © 2020 The Translational Microbiome Research Forum